RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA
Clinical trials for RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…
Matched conditions: RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New hope for hard-to-treat ovarian cancer: three-drug showdown
Disease control OngoingThis study compares three different drug combinations in 444 people with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum chemotherapy. The drugs include a standard chemotherapy (pegylated liposomal doxorubicin) plus one or two immune-boosting o…
Matched conditions: RECURRENT OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC